Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Intrahepatic Cholangiocarcinoma AJCC v8: early-phase trial registry
2 of 9 indexed Stage III Intrahepatic Cholangiocarcinoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Stage III Intrahepatic Cholangiocarcinoma AJCC v8: 9 US clinical trials tracked, 2 recruiting.
Stage III Intrahepatic Cholangiocarcinoma AJCC v8 is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition stage-iii-intrahepatic-cholangiocarcinoma-ajcc-v8
OPEN 2 | RECR 22% | LATE 0 | EARLY 9 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acne (22% recruiting · 27 trials)
Stage III Intrahepatic Cholangiocarcinoma AJCC v8 lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Intrahepatic Cholangiocarcinoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Intrahepatic Cholangiocarcinoma AJCC v8 is recruiting below its size-band peers.
2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Intrahepatic Cholangiocarcinoma AJCC v8 research.
National Cancer Institute (NCI) accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Stage III Intrahepatic Cholangiocarcinoma AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.
-
Stage III Intrahepatic Cholangiocarcinoma AJCC v8 research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
NCT03942328
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic
NCT06058663
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT05564403
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
NCT04175912
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
University of Kansas Medical Center
NCT06178588
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
OHSU Knight Cancer Institute
NCT04251715
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
NCT04708067
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
NCT03201458
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Emory University
NCT03579771
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Intrahepatic Cholangiocarcinoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Intrahepatic Cholangiocarcinoma AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Intrahepatic Cholangiocarcinoma AJCC v8 page
9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Stage III Intrahepatic Cholangiocarcinoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage III Intrahepatic Cholangiocarcinoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Intrahepatic Cholangiocarcinoma AJCC v8 condition card totals 9 registered trials; most-linked intervention Biopsy; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.